Forbius to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Forbius to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Austin, TX, and Montreal, QC (Apr 1, 2020) – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat cancer and fibrosis, announced today that Ilia Tikhomirov, CEO of Forbius, will present a corporate update at the upcoming Solebury Trout Virtual Investor Conference. 

The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details are as follows:

Date/Time: 

Thursday, April 2, 2020, at 2:30p.m. EDT

Access: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36519/indexl.html

 

- END -

 

About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

Forbius is a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer. We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Forbius’ team of TGF-beta biology experts designed a proprietary platform of TGF-beta inhibitors with best-in-class potency and selectivity against the principal disease-driving isoforms 1 & 3. This novel class of TGF-beta inhibitors has proven highly active in preclinical models of fibrosis and cancer and was well-tolerated in long-term toxicology studies. Forbius’ lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Forbius' lead program targeting EGFR is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate (ADC) with a novel tumor-selective mode of action. This program is undergoing Phase 2a clinical trials in EGFR-overexpressing solid tumors.

About TGF-beta 1 & 3

TGF-beta 1 & 3 are the main oncogenic TGF-beta isoforms expressed by many solid tumors. They are believed to play a major role in T-cell suppression, fibrosis and resistance to anti-PD-(L)1 therapies such as nivolumab (Opdivo®) and pembrolizumab (Keytruda®) (Chakravarthy et al., Nature Comm., 2018Tauriello et al., Nature, 2018Mariathasan et al., Nature, 2018).

Contact

Ilia Tikhomirov, CEO, Forbius

ir@forbius.com

Back
Download

Contact

Claudia Resch
info@forbius.com